MAXCYTE, INC. Annual Report - How They Did This Year

I’ve put together a plain-English guide to help you understand MaxCyte’s performance. Instead of digging through complex financial filings, I’ve broken down the key takeaways so you can decide if this company fits your investment goals.

1. What does this company do?

MaxCyte provides the "picks and shovels" for the cell therapy industry. They don't make the medicine themselves. Instead, they provide the specialized technology—called electroporation—that helps other biotech companies engineer cells to treat diseases.

Their technology uses electrical pulses to create temporary pores in cell membranes, allowing companies to deliver genetic material into cells efficiently. It is essential for CAR-T cell therapies and gene editing. MaxCyte earns money by selling their instruments and disposable parts, and by licensing their technology to partners.

2. Financial performance

In 2024, MaxCyte reported $41.3 million in total revenue, a 6% increase from $39.1 million in 2023. Their core business revenue grew 11% to $38.8 million.

The company reported a $36.4 million loss for 2024, compared to a $29.8 million loss in 2023. As of mid-2025, the company’s market value was about $230.7 million, reflecting investor caution regarding their path to profit.

3. Major wins and challenges

The big news this year was the acquisition of Sequre, Inc. This adds new cell-engineering capabilities to their portfolio, allowing MaxCyte to offer more integrated solutions. By the end of 2024, they held 22 Strategic Platform Licenses, which provide long-term, recurring revenue.

However, they face a "chicken-and-egg" challenge. Their success depends on their customers. If a customer’s drug fails a clinical trial, MaxCyte’s business suffers. While over 100 clinical programs use MaxCyte technology, moving from research to commercial manufacturing remains a major industry bottleneck.

4. Financial health and risks

MaxCyte has lost money since its inception, with an accumulated deficit of $275 million by the end of 2024. They expect to keep losing money as they invest in research and expansion.

Key risks include:

• Customer Concentration: Their top three customers provided 35% of their revenue in 2024. Losing even one major partner would hurt their finances.
• The "Milestone" Trap: Some revenue comes from one-time payments when partners hit clinical goals. These payments are unpredictable and volatile.
• Manufacturing Hurdles: They rely on third-party manufacturers. Any supply chain disruption could delay their ability to fulfill orders.
• Need for Cash: They held $185.2 million in cash at the end of 2024. While this provides a runway for a few years, they may eventually need to raise more money. This could mean issuing more shares, which reduces your ownership percentage.

5. Future outlook

Management is focused on scaling their infrastructure and increasing their number of licenses. They aim to become the industry standard for cell engineering. They are betting that as the market for oncology and autoimmune treatments grows, their technology will become increasingly valuable. They are currently upgrading their ExPERT® platform to improve efficiency for commercial-scale manufacturing.

6. The Bottom Line

MaxCyte is a high-risk, high-reward investment. You aren't buying them for current profits; you are betting that their technology will become the backbone of future medicine. If you are risk-averse, their ongoing losses, reliance on a few key customers, and the volatility of the biotech industry may be red flags.

Investor Tip: To track their progress, keep an eye on the number of their partners that successfully move from clinical trials to commercial products. Since MaxCyte’s revenue is tied to the success of these drugs, this is the primary indicator of their long-term growth potential.